date:Dec 04, 2019
t for the product, but BASF hopes to further expand Hepacors footprint in Europe going forward.
The launch of Hepacor in Switzerland marks a major milestone in BASFs plans to commercialize a dedicated solution for NAFLD management globally. Together with Ideogen, the BASF team has undergone a rigorous process to bring Hepacor to continental Europe and address a growing concern for patients with NAFLD, says Christoph Garbotz, Head of Commercial Management Advanced Health Solutions, BASF.
With